# Unbranded engagement > Unbranded engagement provides balanced scientific or educational communication about a disease, unmet need or treatment approach without promoting a specific product. Source: https://www.visfo.health/glossary/unbranded-engagement Updated: 2026-08-16T21:55:00.804003+00:00 What is unbranded engagement? Unbranded engagement is scientific or educational communication about a disease, unmet need, therapeutic area, emerging science or healthcare challenge without promoting or naming a specific product. It aims to provide balanced, factual information that helps healthcare professionals, patients or other stakeholders understand the wider clinical context. It is commonly used before launch or early in a product’s lifecycle to raise awareness, build trust and prepare stakeholders for future innovation. Although it does not contain product promotion, it still requires clear objectives, evidence standards and compliance review. Why does unbranded engagement matter in medical affairs and commercial planning? Unbranded engagement gives [medical affairs](/glossary/medical-affairs) teams a way to support disease education and scientific dialogue before product-specific communication is appropriate. It can identify knowledge gaps, improve understanding of unmet need and create informed discussion around changes in evidence, diagnosis or care pathways. For commercial planning, it can establish the context in which future product positioning will be understood. Medical and commercial teams may contribute to a shared strategic plan, but their activities, content and decision rights must remain appropriately separated. Unbranded communication should not be used as indirect or disguised promotion. How is unbranded engagement planned and run in practice? Teams begin with a defined audience need rather than a product message. [Stakeholder mapping](/glossary/stakeholder-mapping), literature review, advisory activity and field insights can help establish what different groups already understand, where uncertainty remains and which channels are suitable. A practical plan sets out the educational objective, audience, evidence base, content owner, channel, review route and measures of success. Formats may include disease education websites, congress activity, scientific meetings, publications, webinars or field-led discussions. Measures should reflect the objective and may cover relevant reach, content use, quality of engagement, changes in knowledge, questions raised and recurring evidence gaps rather than product interest or sales outcomes. How does a team keep unbranded engagement non-promotional? Content should be accurate, balanced, substantiated and clearly separated from product claims, brand identity and calls to prescribe. The overall impression matters as much as individual words: material may still be promotional if its imagery, timing, mechanism focus or audience targeting makes a particular product readily identifiable and encourages its use. Medical, legal, regulatory and compliance reviewers should assess the content against applicable local rules and the intended audience. Particular care is needed before launch, when discussion of emerging science could imply an unapproved indication, anticipated claim or treatment recommendation. Who owns unbranded engagement? Ownership depends on the purpose. Medical teams usually lead scientific exchange, evidence-led education and activities addressing clinical knowledge gaps. A [medical science liaison](/glossary/medical-science-liaison-msl) may support appropriate scientific discussion and capture insights from healthcare professionals, while commercial teams may lead broader disease-awareness activity where local rules permit. Good governance defines who commissions, writes, reviews, approves, delivers and measures each activity. It also records funding and sponsorship, manages external contributors transparently and prevents unbranded programmes from becoming an informal bridge to product promotion. How is unbranded engagement different from related activities? Unbranded engagement is the wider approach. Disease-awareness communication is a common form of it, usually focused on recognition, burden, diagnosis or care gaps. Scientific exchange is generally more evidence-led and interactive, while engagement with a [thought leader](/glossary/thought-leader) describes the stakeholder relationship rather than whether the content is branded. Branded engagement names or clearly promotes a specific medicine or service and is governed as promotional communication. Unbranded engagement sits before or alongside it, building understanding of the disease and scientific environment without making the product the subject.